Covidien Aims To Double Sales In Emerging Markets By 2017
Covidien plans to double its sales in emerging markets, primarily China and India, to $2 billion over the next five to six years, CEO Jose E. Almeida said during the firm's Sept. 8 investor meeting in New York
More from Archive
More from Scrip
• By
As CEO Anderson backs high prices for innovative drugs in Europe
• By
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
• By
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.